Anti-Parkinson Drugs Global Market Report 2024

The anti-parkinson drugs market size has grown strongly in recent years. It will grow from $9.73 billion in 2023 to $10.43 billion in 2024 at a compound annual growth rate (CAGR) of 7.2%. The growth observed in the historical period can be primarily attributed to several key factors, including the aging population, a higher prevalence of the disease, advancements in healthcare infrastructure, and progress in research and development within the field of anti-Parkinson drugs.

The anti-parkinson drugs market size is expected to see strong growth in the next few years. It will grow to $13.36 billion in 2028 at a compound annual growth rate (CAGR) of 6.4%. The anticipated growth in the forecast period can be attributed to several factors, including increasing awareness about Parkinson's disease and related treatments, advancements in biotechnology, and the emergence of new markets. Additionally, key trends in the forecast period include heightened investment in research and development (R&D), the development of personalized medicine, the pursuit of disease-modifying therapies, drug repurposing, the utilization of telemedicine and remote monitoring, the introduction of biosimilars, and the fostering of research collaborations. These trends and factors collectively contribute to the expansion and development of the anti-Parkinson drug market.

The anticipated growth in the demand for anti-Parkinson drugs is driven by the increasing geriatric population and the rising number of cases of Parkinson's disease (PD). PD is commonly diagnosed in individuals over the age of 60, making it a particular concern for the elderly population. For example, data from the World Health Organization indicates that globally, the proportion of individuals aged 60 or older is expected to reach 1 in 6 by 2030, and this figure is projected to double by 2050, reaching 2.1 billion individuals in this age group. Similarly, data from the UK Parliament's House of Commons Library reveals that the elderly population in the UK is expected to grow significantly, accounting for 24% of the total population (17.4 million people) by 2043. This demographic shift towards an older population is a key driver of the increasing demand for anti-Parkinson drugs, given the higher prevalence of PD in the elderly.

The main categories of anti-Parkinson drugs include levodopa/carbidopa, dopamine receptor agonists, monoamine oxidase type B (MAO-B) inhibitors, catechol-O-methyltransferase (COMT) inhibitors, anticholinergics, and other drugs. Catechol-O-methyltransferase (COMT) inhibitors represent a specific class of drugs used in conjunction with carbidopa-levodopa therapy to manage Parkinson's disease symptoms effectively. These medications can be administered through various routes, including oral, injection, and transdermal methods, and they are typically dispensed through hospital pharmacies, retail pharmacies, and online pharmacies.

The anti-Parkinson drugs market research report is one of a series of new reports that provides anti-Parkinson drugs market statistics, including anti-Parkinson drugs industry global market size, regional shares, competitors with an anti-Parkinson drugs market share, detailed anti-Parkinson drugs market segments, market trends and opportunities, and any further data you may need to thrive in the anti-Parkinson drugs industry. This anti-Parkinson drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The expected growth in the anti-Parkinson drugs market is being propelled by the increasing incidence of mental health disorders. Mental health disorders represent a clinically significant impairment in an individual's cognitive, emotional regulation, or behavior, often associated with distress and functional impairment in various areas of life. The rise in mental health disorders has a direct impact on the anti-Parkinson drugs market, as these drugs play a crucial role in mitigating and treating these disorders. For example, data from the Health and Social Care Information Centre in the UK reveals a notable increase in the proportion of 17- to 19-year-olds with suspected mental disorders, rising from 17.4% in 2021 to 25.7% in 2022. This data illustrates the growing prevalence of mental health disorders, which, in turn, drives the demand for anti-Parkinson drugs. The connection between these two factors underscores the importance of anti-Parkinson drugs in addressing the mental health needs of individuals affected by Parkinson's disease and related conditions.

The anticipated growth of the anti-Parkinson's drug market may face limitations due to the high cost associated with the treatment of Parkinson's disease. According to statistics from the Michael J. Fox Foundation for Parkinson's Research, the economic burden of Parkinson's disease is on the rise and affects patients, their families, and the federal government. In the United States, the overall cost of Parkinson's disease amounts to $51.9 billion annually, with $25.4 billion allocated to direct medical costs, including expenses related to hospitalization and medication. This significant financial burden on individuals, families, and healthcare systems underscores the high cost of managing Parkinson's disease. Consequently, the expense of treating the condition can potentially restrict access to anti-Parkinson drugs and influence the market's growth dynamics. Finding cost-effective solutions and approaches to Parkinson's disease treatment will be a key consideration for stakeholders in the anti-Parkinson's drug market.

Major companies in the anti-Parkinson drugs market are committed to innovation and have introduced products like Safinamide to enhance the quality of care for patients with Parkinson's disease. Safinamide is an anti-Parkinson drug designed to alleviate symptoms and improve the overall quality of life for individuals with Parkinson's disease. For example, in April 2021, Optimus Pharma Private Limited, an India-based pharmaceutical company, introduced Safinamide after obtaining approval from the Drug Controller General of India (DCGI), the regulatory authority responsible for drug oversight in India. Safinamide is indicated as an adjunctive therapy to be used in conjunction with levodopa or carbidopa for patients with Parkinson's disease. This introduction aims to provide robust and affordable treatment options while ensuring greater accessibility to patients managing Parkinson's disease. Innovation and accessibility are essential factors in advancing care for individuals affected by Parkinson's disease.

A significant trend in the anti-Parkinson drugs market is the increased investment from both government and corporate sources in research and development for drugs related to Parkinson's disease. For example, in August 2022, the Parkinson's Foundation, a prominent national organization in the United States, announced a substantial investment of $5.7 million into 33 research projects. This funding is aimed at accelerating cutting-edge research in the field of Parkinson's disease. By providing research grants, the foundation supports scientists in conducting innovative studies on various aspects of Parkinson's disease. The ultimate goal is to develop new therapies, treatments, and, ideally, a cure for the approximately 10 million individuals worldwide who are affected by this debilitating neurological condition. As a result, the increased investments in Parkinson's drug development are expected to be a driving force in the anti-Parkinson drugs market.

AbbVie Inc., a prominent pharmaceutical company based in the United States, made a strategic move in October 2023 by acquiring Mitokinin for $110 million. This acquisition is part of AbbVie's efforts to bolster its neuroscience pipeline and expand treatment options for individuals with Parkinson's disease. Mitokinin, a biotechnology company also based in the United States, specializes in providing innovative treatments for Parkinson disease (PD).

Major companies operating in the anti-parkinson drugs market include GlaxoSmithKline plc, Pfizer Inc., Merck Co., Novartis AG, F. Hoffmann-La Roche AG, UCB S.A, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Mylan NV, C.H. Boehringer Sohn AG & Co. KG, Orion Pharma Ltd., ACADIA Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Wockhardt Ltd., Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., US WorldMeds LLC, Zydus Lifesciences Limited, Chemical Industrial & Pharmaceutical Laboratories Ltd., Strides Shasun Ltd., Axcan Pharma Inc., Upsher-Smith Laboratories LLC, H. Lundbeck A/S, Vertical Pharmaceuticals LLC, Zambon SPA, M Somerset Pharmaceuticals Inc., Valeant Pharmaceuticals International Inc., Neurocrine Biosciences Inc., Supernus Pharmaceuticals Inc.

North America was the largest region in the anti-Parkinson drugs market in 2023. Middle East is expected to be the fastest-growing region in the anti-parkinson drugs market during the forecast period. The regions covered in the anti-parkinson drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the anti-parkinson drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The anti-parkinson drugs market consists of sales of catechol-O-methyl transferase [COMT] inhibitors, anticholinergic drugs, and amantadine. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.